[Molecular characterization of the early phase of the novel influenza A H1N1 (2009) viruses].
Xian Qi(Peking University), Hua Wang(Chinese Center For Disease Control and Prevention), Bin Wu(China Astronaut Research and Training Center), Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Liang Li(Tongji University), Rongqiang Zu(Chinese Center For Disease Control and Prevention), Fenyang Tang(Jiangsu Provincial Center for Disease Control and Prevention), Haitao Yang(Fujian Medical University)
PubMed
January 1, 2010
Cited by 1
Related Papers
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
Co-infection with respiratory pathogens among COVID-2019 cases
|Virus Research|2020|637
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China
|The Journal of Infectious Diseases|2020|391
A Family Cluster of Infections by a Newly Recognized Bunyavirus in Eastern China, 2007: Further Evidence of Person-to-Person Transmission
|Clinical Infectious Diseases|2011|268
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|Signal Transduction and Targeted Therapy|2021|204